Beclosept Ointment combines Beclomethasone 0.025% w/w, a topical corticosteroid, with Salicylic Acid 3% w/w, a keratolytic agent. Together, they help reduce inflammation, remove thickened skin layers, and relieve symptoms of psoriasis, eczema, dermatitis, and chronic inflammatory skin disorders.
Salicylic Acid softens and removes scales, enhancing the penetration of Beclomethasone for faster therapeutic action. Beclomethasone works by reducing redness, swelling, itching, and irritation through targeted suppression of inflammatory pathways.
This product belongs to the dermatology and skin treatment segment and is widely prescribed by dermatologists and skin specialists. Due to strong demand in chronic care therapy, it ensures consistent repeat orders in hospitals, clinics, and pharmacies.
Beclosept Ointment is available for PCD pharma franchise, institutional supply, private labeling, export, and third-party manufacturing, offering excellent profit margins in the growing dermatology market.